Product Images Rocuronium Bromide

Not available.*

This is a description of a medical product called "Vecuronium Bromide Injection" used as a muscle relaxant during anesthesia. It contains United States address and a warning message about possible allergic reactions. The rest of the text provides information about the product's identification code and its manufacturing details.*

Description: Rocuronium Bromide is a drug used for intubation. The table shows the percentage of patients with excellent/good intubating conditions and the time to completion after administration of the drug at different doses for adults, infants, and pediatric patients.*

This appears to be a table showing the dose, time to a certain level of muscle block, time to maximum block, and clinical duration of the muscle relaxant drug Rocuronium Bromide, administered intravenously in different doses for adults, geriatric patients, infants, and pediatric patients. However, without further context or explanation of the units used, it is difficult to provide a more detailed description.*

This appears to be a table showing pharmacokinetic (PK) parameters for patients in different age ranges, listed in days, months, and years. The table includes information on clearance (CL), volume of distribution (O), and half-life (1/2 B) for patients between 28 days old and 17 years old. The numbers in parentheses likely represent a range or variability in the values.*

This appears to be a chart showing the recommended dosage of rocuronium bromide for different age groups, from neonates to adolescents. It also shows the time it takes for maximum block and reappearance of T3 after administration over a period of time. However, some of the text is cut off, making it difficult to interpret some of the values.*

This is a figure showing the duration of clinical effect versus the initial dose of Rocuronium Bromide by age group. Median, 25th, and 75th percentiles, as well as individual values, are displayed. The age groups are categorized as 18-64 years, greater than or equal to 65 years, 3 months to 1 year, and 1-12 years, along with the dosages in milligrams per kilogram.*

This is a table that shows PK (pharmacokinetic) parameters for a certain drug in two groups of people: adults (aged 27-58 years) and geriatrics (aged 65 years and above). The table displays the clearance (L/kg/hr), volume of distribution at steady-state (L/kg), and half-life of elimination (hr) of the drug in each group.*

This is a table comparing PK parameters between patients with normal renal function, renal transplant, and hepatic dysfunction. It reports clearance, volume of distribution at steady state, and elimination half-life (t1/2 B) for each group of patients.*

This text provides pharmacokinetic parameters (clearance, volume of distribution and elimination half-life) for a medication for different age ranges of pediatric patients: 3 to 12 months, 1 to less than 3 years, and 3 to 8 years.*

This appears to be a table indicating the infusion delivery rate (mL/hr) for drug dosages based on the patient's weight (in pounds) and drug delivery rate (mcg/kg/min). The first row lists patient weights from 45 to 160 pounds in increments of 10, while the first column lists drug delivery rates from 4 to 100 mcg/kg/min in increments of 5. However, the table is not complete, as some values are missing.*

This table shows drug infusion rates based on patient weight, in pounds (Ibs), and drug delivery rate in mcg/kg/min. The infusion delivery rate is also provided in mL/hr. The lower rows of the table correspond to higher patient weights. Each column represents a different drug delivery rate.*

This table shows the drug delivery rates (mcg/kg/min) for patients of different weights (in lbs). The corresponding infusion delivery rates (mL/hr) for different weight ranges are also given in the table.*

This is information related to the dosing and administration of a medication, specifically the dosage information for specific populations. The text also includes warnings and precautions regarding the risk of death due to medication errors and the possibility of residual paralysis.*